Skip to Main Content

Paper Details

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
J Thorac Oncol
17
2023
ALK, Advanced NSCLC, EGFR, KEAP1, KRAS, NSCLC, NSCLCs, PD-L1, SMARCA4, SMARCA4 mutation, SMARCA4 mutations, STK11, TMB, advanced NSCLC, neutrophil, nonsquamous NSCLC, patient, patients, platinum, programmed cell death protein 1, programmed death-ligand 1, tumor
Author NameAffiliation
Marc LadanyiMemorial Sloan Kettering Cancer Center
Subba R DigumarthyMassachusetts General Hospital Cancer Center
Xihong LinHarvard T.H. Chan School of Public Health, Harvard University
Xihong LinHarvard T.H. Chan School of Public Health, Harvard University
  • 1 - 4

Datasets

Release 1.2